Our Website Uses Cookies 

We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.

For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Sarah Turner is an associate in the corporate practice group in the London office.

Ms. Turner advises both private and public companies on a wide range of matters, including mergers and acquisitions, private financings, general corporate governance and capital market transactions, acting for both corporate issuers and financial institutions in relation to IPO’s and equity offerings on the Main and AIM markets of the LSE. She has particular expertise in advising on transactions in the life sciences and technology industries.

  • Represented the management team of The Foundry in relation to HgCapital’s investment under the terms of which HgCapital assumed majority ownership from The Carlyle Group for an enterprise value of £200 million ($312 million USD). The Foundry is a leading provider of award-winning creative software.
  • Acted for Cenkos Securities plc as sole co-ordinator and bookrunner to the AA Group plc on its £1,385 billion IPO on the London Main Market.
  • Advised Consort Medical plc, listed on the London Main Market, in relation to its £98.9 million rights issue in connection with its £230 million acquisition of Aesica Holdco Limited.
  • Acted for Horizon Discovery Group plc:
    • on its IPO and admission to the AIM market of the London Stock Exchange, raising approximately £40 million before expenses for Horizon and a further £28.6 million for selling shareholders; and
    • on its placing and sale of existing shares to raise £25 million before expenses for Horizon and a further £15 million for selling shareholders.
  • Advised Vectura Group Plc, a product development company listed on the London Main Market, on its acquisition of German pharmaceutical company Activaero GmbH for a total consideration of €130 million (£108 million) and related £52 million fundraising.
  • Advised Lombard Medical, Inc. on its Scheme of Arrangement and $55 million U.S. initial public offering and the listing of the company’s ordinary shares on the NASDAQ Global Market.
  • Acted for Charles Stanley Securities, as NOMAD, and WG Partners as financial adviser and broker to Venture Life Group plc, on its IPO and admission to AIM.   
  • Represented Rightster Group plc, a global online video distribution and monetisation network on its IPO and admission to AIM and associated fundraising of approximately £20 million.
  • Advised AstraZeneca and MedImmune, its global biologics research and development arm, on the acquisition of Spirogen, a privately-held biotechnology company focused on antibody-drug conjugate technology for use in oncology.
  • Advised Canaccord Genuity Limited as nominated adviser and joint broker to AIM-quoted Lombard Medical Technologies plc on a £21 million placing of ordinary shares.
  • Advised ReNeuron Group plc, an AIM listed stem cell therapy company, on its £33 million fundraising.
  • Represented Oxford Biomedica plc, listed on the London Main Market, on its 2010 placing and open offer to raise approximately £20 million and its 2012 firm placing and open offer to raise up to £16 million.
  • Acted for a US multinational pharmaceutical company on the integration of a major acquisition in over 60 countries.
  • Legal 500 UK, Flotations: Small & Mid-cap (2016)